GT
CSTL icon

Glenmede Trust’s Castle Biosciences CSTL Stock Holding History

Glenmede Trust’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$201K Sell
8,168
-22
-0.3% -$721 ﹤0.01% 1315
2025
Q4 		$319K Buy
+8,190
New +$264K ﹤0.01% 1114

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glenmede Trust's CSTL Position: Q1 2026 in Review

Glenmede Trust reduced its Castle Biosciences (CSTL) stake by 0.27% in Q1 2026, selling an estimated $721 and leaving 8,168 shares worth $201K. The position accounts for ﹤0.01% of the portfolio, ranked #1315.

Glenmede Trust first reported a position in CSTL in Q4 2025 and has held it in 2 quarters since. The position peaked at $319K in Q4 2025. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Glenmede Trust held 8,168 shares of Castle Biosciences worth $201K as of Q1 2026.
  • Glenmede Trust sold 22 Castle Biosciences shares in Q1 2026, an estimated $721.
  • Castle Biosciences made up ﹤0.01% of Glenmede Trust's portfolio in Q1 2026, its #1315 holding.
  • Glenmede Trust first reported a position in Castle Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Glenmede Trust's Castle Biosciences position peaked at $319K in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.